N-α-(9-Fluorenylmethoxycarbonyl)-N-ω-mesitylenesulfonyl-L-arginine
Need Assistance?
  • US & Canada:
    +
  • UK: +

N-α-(9-Fluorenylmethoxycarbonyl)-N-ω-mesitylenesulfonyl-L-arginine

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
Fmoc-Amino Acids
Catalog number
BAT-005468
CAS number
88743-97-9
Molecular Formula
C30H34N4O6S
Molecular Weight
578.68
N-α-(9-Fluorenylmethoxycarbonyl)-N-ω-mesitylenesulfonyl-L-arginine
IUPAC Name
(2S)-5-[[amino-[(2,4,6-trimethylphenyl)sulfonylamino]methylidene]amino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)pentanoic acid
Synonyms
Fmoc-Arg(Mts)-OH; (2S)-5-[[amino-[(2,4,6-trimethylphenyl)sulfonylamino]methylidene]amino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)pentanoic acid; Nalpha-Fmoc-Nomega-(mesitylene-2-sulfonyl)-L-arginine
Purity
≥ 95%
Density
1.350 g/cm3
Storage
Store at 2-8 °C
InChI
InChI=1S/C30H34N4O6S/c1-18-15-19(2)27(20(3)16-18)41(38,39)34-29(31)32-14-8-13-26(28(35)36)33-30(37)40-17-25-23-11-6-4-9-21(23)22-10-5-7-12-24(22)25/h4-7,9-12,15-16,25-26H,8,13-14,17H2,1-3H3,(H,33,37)(H,35,36)(H3,31,32,34)/t26-/m0/s1
InChI Key
JHMUQIZIPLJEHW-SANMLTNESA-N
Canonical SMILES
CC1=CC(=C(C(=C1)C)S(=O)(=O)NC(=NCCCC(C(=O)O)NC(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24)N)C

N-α-(9-Fluorenylmethoxycarbonyl)-N-ω-mesitylenesulfonyl-L-arginine (Fmoc-Arg(Mts)-OH) stands as a derivative of the amino acid arginine, widely utilized in peptide synthesis. Embark on a journey to discover the versatile applications of this compound:

Solid-Phase Peptide Synthesis (SPPS): Venture into the intricate world of solid-phase peptide synthesis (SPPS), where Fmoc-Arg(Mts)-OH emerges as a key protagonist in elongating peptide chains containing arginine. Guided by its Fmoc group, this compound facilitates the stepwise addition of amino acids to the growing peptide structure, safeguarding the arginine side chain from unwanted reactions. Witness its indispensable role in crafting biologically potent peptides and proteins with unparalleled specificity and yield, unlocking new frontiers in peptide chemistry.

Drug Development: Behold the groundbreaking impact of Fmoc-Arg(Mts)-OH in pharmaceutical research, driving the synthesis of peptide-based drug candidates. The modified arginine residue elevates the biological efficacy, stability, and targeted delivery of therapeutic peptides, heralding a new era of peptide drug discovery. Immerse yourself in the realm of drug development empowered by this compound’s versatility, as it fuels the creation of innovative peptide medications combatting a diverse range of diseases, from cancer to diabetes and infectious afflictions, reshaping the landscape of therapeutic interventions.

Protein Engineering: Embark on a voyage into the domain of protein engineering, where Fmoc-Arg(Mts)-OH shines brightly by introducing arginine residues into synthetic protein frameworks. This strategic modification enhances the protein’s solubility, binding affinity, and overall robustness, paving the way for the design of tailor-made proteins for industrial catalysts, advanced biomaterials, and cutting-edge therapeutic applications. Journey into the realm of transformative protein design with Fmoc-Arg(Mts)-OH at the helm, revolutionizing the field of molecular engineering with its versatility and precision.

Biochemical Studies: Enter the intricate realm of biochemical studies, where researchers harness Fmoc-Arg(Mts)-OH to unravel the enigmatic role of arginine residues in protein function and interactions. By incorporating this derivative into peptides and proteins, scientists unravel the intricate effects of arginine modifications on enzyme activity, signal transduction pathways, and protein-protein interactions, shedding light on the intricate web of molecular interactions. Explore the complex dynamics of arginine-rich proteins and gain invaluable insights into the intricate relationships between protein structure and function, charting new paths in biochemical research and molecular understanding.

1. Preparation of protected peptidyl thioester intermediates for native chemical ligation by Nalpha-9-fluorenylmethoxycarbonyl (Fmoc) chemistry: considerations of side-chain and backbone anchoring strategies, and compatible protection for N-terminal cysteine
C M Gross, D Lelièvre, C K Woodward, G Barany J Pept Res. 2005 Mar;65(3):395-410. doi: 10.1111/j.1399-3011.2005.00241.x.
Native chemical ligation has proven to be a powerful method for the synthesis of small proteins and the semisynthesis of larger ones. The essential synthetic intermediates, which are C-terminal peptide thioesters, cannot survive the repetitive piperidine deprotection steps of N(alpha)-9-fluorenylmethoxycarbonyl (Fmoc) chemistry. Therefore, peptide scientists who prefer to not use N(alpha)-t-butyloxycarbonyl (Boc) chemistry need to adopt more esoteric strategies and tactics in order to integrate ligation approaches with Fmoc chemistry. In the present work, side-chain and backbone anchoring strategies have been used to prepare the required suitably (partially) protected and/or activated peptide intermediates spanning the length of bovine pancreatic trypsin inhibitor (BPTI). Three separate strategies for managing the critical N-terminal cysteine residue have been developed: (i) incorporation of N(alpha)-9-fluorenylmethoxycarbonyl-S-(N-methyl-N-phenylcarbamoyl)sulfenylcysteine [Fmoc-Cys(Snm)-OH], allowing creation of an otherwise fully protected resin-bound intermediate with N-terminal free Cys; (ii) incorporation of N(alpha)-9-fluorenylmethoxycarbonyl-S-triphenylmethylcysteine [Fmoc-Cys(Trt)-OH], generating a stable Fmoc-Cys(H)-peptide upon acidolytic cleavage; and (iii) incorporation of N(alpha)-t-butyloxycarbonyl-S-fluorenylmethylcysteine [Boc-Cys(Fm)-OH], generating a stable H-Cys(Fm)-peptide upon cleavage. In separate stages of these strategies, thioesters are established at the C-termini by selective deprotection and coupling steps carried out while peptides remain bound to the supports. Pilot native chemical ligations were pursued directly on-resin, as well as in solution after cleavage/purification.
2. A 'conovenomic' analysis of the milked venom from the mollusk-hunting cone snail Conus textile--the pharmacological importance of post-translational modifications
Zachary L Bergeron, et al. Peptides. 2013 Nov;49:145-58. doi: 10.1016/j.peptides.2013.09.004. Epub 2013 Sep 18.
Cone snail venoms provide a largely untapped source of novel peptide drug leads. To enhance the discovery phase, a detailed comparative proteomic analysis was undertaken on milked venom from the mollusk-hunting cone snail, Conus textile, from three different geographic locations (Hawai'i, American Samoa and Australia's Great Barrier Reef). A novel milked venom conopeptide rich in post-translational modifications was discovered, characterized and named α-conotoxin TxIC. We assign this conopeptide to the 4/7 α-conotoxin family based on the peptide's sequence homology and cDNA pre-propeptide alignment. Pharmacologically, α-conotoxin TxIC demonstrates minimal activity on human acetylcholine receptor models (100 μM, <5% inhibition), compared to its high paralytic potency in invertebrates, PD50 = 34.2 nMol kg(-1). The non-post-translationally modified form, [Pro](2,8)[Glu](16)α-conotoxin TxIC, demonstrates differential selectivity for the α3β2 isoform of the nicotinic acetylcholine receptor with maximal inhibition of 96% and an observed IC50 of 5.4 ± 0.5 μM. Interestingly its comparative PD50 (3.6 μMol kg(-1)) in invertebrates was ~100 fold more than that of the native peptide. Differentiating α-conotoxin TxIC from other α-conotoxins is the high degree of post-translational modification (44% of residues). This includes the incorporation of γ-carboxyglutamic acid, two moieties of 4-trans hydroxyproline, two disulfide bond linkages, and C-terminal amidation. These findings expand upon the known chemical diversity of α-conotoxins and illustrate a potential driver of toxin phyla-selectivity within Conus.
3. Syntheses of T(N) building blocks Nalpha-(9-fluorenylmethoxycarbonyl)-O-(3,4,6-tri-O-acetyl-2-azido-2-deoxy-alpha-D-galactopyranosyl)-L-serine/L-threonine pentafluorophenyl esters: comparison of protocols and elucidation of side reactions
Mian Liu, Victor G Young Jr, Sachin Lohani, David Live, George Barany Carbohydr Res. 2005 May 23;340(7):1273-85. doi: 10.1016/j.carres.2005.02.029.
T(N) antigen building blocks Nalpha-(9-fluorenylmethoxycarbonyl)-O-(3,4,6-tri-O-acetyl-2-azido-2-deoxy-alpha-D-galactopyranosyl)-L-serine/L-threonine pentafluorophenyl ester [Fmoc-L-Ser/L-Thr(Ac3-alpha-D-GalN3)-OPfp, 13/14] have been synthesized by two different routes, which have been compared. Overall isolated yields [three or four chemical steps, and minimal intermediary purification steps] of enantiopure 13 and 14 were 5-18% and 6-10%, respectively, based on 3,4,6-tri-O-acetyl-D-galactal (1). A byproduct of the initial azidonitration reaction of the synthetic sequence, that is, N-acetyl-3,4,6-tri-O-acetyl-2-azido-2-deoxy-alpha-D-galactopyranosylamine (5), has been characterized by X-ray crystallography, and shown by 1H NMR spectroscopy to form complexes with lithium bromide, lithium iodide, or sodium iodide in acetonitrile-d3. Intermediates 3,4,6-tri-O-acetyl-2-azido-2-deoxy-alpha-D-galactopyranosyl bromide (6) and 3,4,6-tri-O-acetyl-2-azido-2-deoxy-beta-D-galactopyranosyl chloride (7) were used to glycosylate Nalpha-(9-fluorenylmethoxycarbonyl)-L-serine/L-threonine pentafluorophenyl esters [Fmoc-L-Ser/L-Thr-OPfp, 11/12]. Previously undescribed low-level dehydration side reactions were observed at this stage; the unwanted byproducts were easily removed by column chromatography.
Online Inquiry
Verification code
Inquiry Basket